Sirona Biochem Brings In Former Bayer Executive Following AbbVie Deal

Sirona Biochem Corp. (TSX-V: SBM) is tapping into the 30 years of experience of former Bayer executive Dr. Wolfgang Bieber to help bring the company to the next level. The appointment comes just days after Sirona Biochem signed an exclusive global licensing agreement with Allergan Aesthetics, an AbbVie company.

VANCOUVER, British Columbia - June 20, 2022 - PRLog -- Sirona Biochem announced Monday that it would be bringing Dr. Bieber into its Advisory Board. He will also be acting as a direct consultant to the company's Board of Directors. Part of his job will be to form new partnerships with chemical manufacturers in Europe. He will also help restructure the company to ensure sustainable growth.

Sirona Biochem CEO Dr. Howard Verrico said the company would stand to benefit from Dr. Bieber's years of experience and his extensive network within the biotech industry. He added that Dr. Bieber's guidance would be crucial as Sirona Biochem enters a new phase following its deal with AbbVie's Allergan Aesthetics.

In the company's press release, Dr. Bieber commented that he was looking forward to working with Sirona Biochem. He added that he was eager to contribute his experience and network to further accelerate its growth. Dr. Bieber acknowledged that Sirona Biochem's unique approach to chemistry presents incredible potential.

Dr. Bieber worked for Bayer as the Senior Vice-President in charge of operations of its biological production in the U.S. and its global agrochemical production. He is a key figure responsible for the success of products such as Kogenate®, one of the world's largest recombinant protein products. He was pivotal in helping the product reach annual sales of more than $1 billion.

He directly managed more than 1,250 employees, with direct expenses of over $300 million and capital expenses of more than $200 million throughout his career. During his tenure, Dr. Bieber was strongly involved in M&A activities, including major mergers such as with Aventis CropScience in 2001.

Following the completion of its exclusive licensing deal with AbbVie for its library of industry-disrupting skincare compounds, including the breakthrough TFC-1067, Sirona Biochem is presently adopting several initiatives to boost growth and pipeline development.

Sirona Biochem's novel carbohydrate compounds are licensed to leading biotech companies worldwide in return for licensing fees, milestone fees, and ongoing royalty payments. Its development focus is on high-valued programs selected for their core expertise in the area, market potential, development timeline, and return on investment.

To learn more, visit their website: https://www.sironabiochem.com/

Or download their Investor's Presentation – Sirona Biochem Investor's Presentation